GlassScriptPhysician profile
Srinivas Rangu
NPI 1902963655
$4,097.90
in general payments reported to CMS, 2019-2025
33 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $758 · 2021: $756 · 2022: $378 · 2023: $469 · 2024: $598 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486 · Education: $39.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.39 |
| Education | $39.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $872.15 | 2019-2024 | Farxiga, Breztri |
| Pfizer INC. | $542.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $534.70 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $510.64 | 2019-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $224.41 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $129.50 | 2019-2025 | |
| Amarin Pharma, INC. | $125.82 | 2020-2021 | |
| Astellas Pharma US INC | $106.74 | 2021-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.84 | 2021-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $99.54 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $89.70 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.70 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $77.82 | 2019-2023 | Steglatro, Steglujan, Belsomra |
| Lilly USA, LLC | $70.05 | 2020-2024 | Mounjaro, Trulicity, Jardiance |
| Xeris Pharmaceuticals, INC. | $61.17 | 2022-2023 | Gvoke Hypopen |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45.29 | 2020-2025 | Evenity, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $44.00 | 2024-2025 | Rexulti |
| Boston Scientific Corporation | $37.86 | 2023 | Watchman Access System |
| Sanofi-Aventis U.S. LLC | $32.70 | 2019-2024 | |
| Abbvie INC. | $32.66 | 2024-2025 | |
| Abbott Laboratories | $30.75 | 2021-2024 | Freestyle Libre 3 |
| Cashflow Solutions, LLC | $29.22 | 2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Scpharmaceuticals INC. | $27.16 | 2024 | |
| Sunovion Pharmaceuticals INC. | $23.95 | 2019 | |
| Dexcom, INC. | $23.64 | 2024 | Dexcom G6 Transmitter |
| Abiomed | $23.10 | 2025 | |
| Almatica Pharma LLC | $22.90 | 2021 | |
| Eisai INC. | $20.75 | 2020 | |
| Ge Healthcare | $17.16 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.09 | 2025 | Zoryve |
| Arbor Pharmaceuticals, INC. | $13.27 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.00 | 2022 | |
| Phathom Pharmaceuticals, INC. | $11.15 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Rangu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.